Black Bird Biotech, Inc.: 10-Q filed 2023-11-20

Name: Black Bird Biotech, Inc.: 10-Q filed 2023-11-20
Creator: Black Bird Biotech, Inc.
License: https://creativecommons.org/licenses/by/4.0/

What Black Bird Biotech, Inc. reported in its quarterly report filed 2023-11-20 (fiscal Q3 2023): 36 published measures, 110 facts as tagged in accession 0001477932-23-008686.

This filing

Form: 10-Q (quarterly report)
Filed: 2023-11-20
Fiscal period: fiscal Q3 2023
Accession: 0001477932-23-008686 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; a measure with a published history links to it, and the history shows the latest-filed value per period. All Black Bird Biotech, Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

Period	Value	Unit	Days
At 2023-09-30	98,779	USD
At 2022-12-31	218,508	USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

Period	Value	Unit	Days
At 2023-09-30	1,021,557	USD
At 2022-12-31	868,678	USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

Period	Value	Unit
At 2023-09-30	-922,778	USD
At 2023-06-30	-871,289	USD
At 2023-03-31	-726,004	USD
At 2022-12-31	-650,170	USD
At 2022-09-30	-657,600	USD
At 2022-06-30	-395,045	USD
At 2022-03-31	-148	USD
At 2021-12-31	670,210	USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

Period	Value	Unit	Days
2023-07-01 to 2023-09-30	-131,225	USD	92
2023-04-01 to 2023-06-30	-196,955	USD	91
2023-01-01 to 2023-03-31	-266,934	USD	90
2022-04-01 to 2022-06-30	-522,594	USD	91
2022-01-01 to 2022-03-31	-670,358	USD	90

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

Period	Value	Unit	Days
2023-01-01 to 2023-09-30	-118,813	USD	273
2022-01-01 to 2022-09-30	-918,331	USD	273

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

Period	Value	Unit	Days
2023-07-01 to 2023-09-30	3,937	USD	92
2023-01-01 to 2023-09-30	24,244	USD	273
2022-07-01 to 2022-09-30	25,739	USD	92
2022-01-01 to 2022-09-30	70,484	USD	273

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

Period	Value	Unit	Days
2023-01-01 to 2023-09-30	80,094	USD	273
2022-01-01 to 2022-09-30	484,741	USD	273

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

Period	Value	Unit	Days
2023-01-01 to 2023-09-30	0	USD	273
2022-01-01 to 2022-09-30	0	USD	273

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

Period	Value	Unit	Days
At 2023-09-30	-4,875,063	USD
At 2022-12-31	-4,279,949	USD

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

Period	Value	Unit	Days
2023-07-01 to 2023-09-30	1,918,026,987	shares	92
2023-01-01 to 2023-09-30	1,634,943,335	shares	273
2022-07-01 to 2022-09-30	335,129,995	shares	92
2022-01-01 to 2022-09-30	372,484,608	shares	273

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

Period	Unit	Days
2023-07-01 to 2023-09-30	USD/shares	92
2023-01-01 to 2023-09-30	USD/shares	273
2022-07-01 to 2022-09-30	USD/shares	92
2022-01-01 to 2022-09-30	USD/shares	273

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

Period	Unit	Days
2023-07-01 to 2023-09-30	USD/shares	92
2023-01-01 to 2023-09-30	USD/shares	273
2022-07-01 to 2022-09-30	USD/shares	92
2022-01-01 to 2022-09-30	USD/shares	273

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

Period	Unit	Days
2023-07-01 to 2023-09-30	USD	92
2023-01-01 to 2023-09-30	USD	273
2022-07-01 to 2022-09-30	USD	92
2022-01-01 to 2022-09-30	USD	273

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

Period	Value	Unit	Days
2023-07-01 to 2023-09-30	-10,884	USD	92
2023-01-01 to 2023-09-30	-188,154	USD	273
2022-07-01 to 2022-09-30	-157,147	USD	92
2022-01-01 to 2022-09-30	-1,077,388	USD	273

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

Period	Value	Unit	Days
At 2023-09-30	91,132	USD
At 2022-12-31	135,088	USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

Period	Value	Unit	Days
2023-07-01 to 2023-09-30	120,466	USD	92
2023-01-01 to 2023-09-30	407,311	USD	273
2022-07-01 to 2022-09-30	46,535	USD	92
2022-01-01 to 2022-09-30	255,913	USD	273

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

Period	Value	Unit	Days
At 2023-09-30	1,018,682	USD
At 2022-12-31	868,678	USD

Net finite-lived intangible assets

Finite-lived intangible assets after amortization. This excludes goodwill and should not be combined with indefinite-lived intangible assets without checking scope.

Period	Value	Unit	Days
At 2023-09-30	190,000	USD

Net current accounts receivable

Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.

Period	Value	Unit	Days
At 2023-09-30	1,553	USD
At 2022-12-31	2,259	USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

Period	Value	Unit	Days
2023-07-01 to 2023-09-30	12,302	USD	92
2023-01-01 to 2023-09-30	199,949	USD	273
2022-07-01 to 2022-09-30	170,527	USD	92
2022-01-01 to 2022-09-30	1,108,888	USD	273

Net inventory

Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.

Period	Value	Unit	Days
At 2023-09-30	75,462	USD
At 2022-12-31	88,381	USD

Gross profit

Revenue less the costs directly attributed to the goods or services sold. It precedes other operating expenses and is not net income.

Period	Value	Unit	Days
2023-07-01 to 2023-09-30	1,418	USD	92
2023-01-01 to 2023-09-30	11,795	USD	273
2022-07-01 to 2022-09-30	13,380	USD	92
2022-01-01 to 2022-09-30	31,500	USD	273

Cost of revenue

Costs attributed to goods produced and sold and services provided during the period. This is not the sum of every operating expense.

Period	Value	Unit	Days
2023-07-01 to 2023-09-30	2,519	USD	92
2023-01-01 to 2023-09-30	12,449	USD	273
2022-07-01 to 2022-09-30	12,359	USD	92
2022-01-01 to 2022-09-30	38,984	USD	273

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

Period	Value	Unit	Days
At 2023-09-30	1,785,430,168	shares
At 2022-12-31	310,695,330	shares

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

Period	Value	Unit
At 2023-09-30	5,729	USD
At 2022-12-31	44,448	USD
At 2022-09-30	66,176	USD
At 2021-12-31	499,766	USD

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

Period	Value	Unit	Days
At 2023-09-30	2,167,815	USD
At 2022-12-31	3,320,042	USD

Operating lease right-of-use asset

Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.

Period	Value	Unit
At 2023-09-30	2,875	USD
At 2023-01-09	17,195	USD
At 2022-12-31	0	USD

Operating lease liability

Present value of remaining operating lease payments. Discount-rate choices and lease terms affect the amount; it is not the sum of undiscounted future rent.

Period	Value	Unit	Days
At 2023-09-30	4,329	USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

Period	Value	Unit	Days
2023-07-01 to 2023-09-30	-131,227	USD	92
2023-01-01 to 2023-09-30	-595,114	USD	273
2022-07-01 to 2022-09-30	-67,646	USD	92
2022-01-01 to 2022-09-30	-1,417,745	USD	273

Profit or loss including noncontrolling interests

Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.

Period	Value	Unit	Days
2023-07-01 to 2023-09-30	-131,227	USD	92
2023-01-01 to 2023-09-30	-595,114	USD	273
2022-07-01 to 2022-09-30	-224,793	USD	92
2022-01-01 to 2022-09-30	-1,417,745	USD	273

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

Period	Value	Unit	Days
2023-07-01 to 2023-09-30	6,397	USD	92
2023-01-01 to 2023-09-30	163,342	USD	273
2022-07-01 to 2022-09-30	102,398	USD	92
2022-01-01 to 2022-09-30	559,550	USD	273

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

Period	Value	Unit	Days
2023-07-01 to 2023-09-30	1,118	USD	92
2023-01-01 to 2023-09-30	3,355	USD	273
2022-07-01 to 2022-09-30	1,118	USD	92
2022-01-01 to 2022-09-30	3,355	USD	273

Amortization of intangible assets

Amortization recognized on finite-lived intangible assets. It follows acquisition accounting and does not indicate the intangibles are losing usefulness at that rate.

Period	Value	Unit	Days
2023-01-01 to 2023-09-30	0	USD	273
2022-01-01 to 2022-09-30	84,444	USD	273

Interest paid, net

Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.

Period	Value	Unit	Days
2023-01-01 to 2023-09-30	15,377	USD	273
2022-01-01 to 2022-09-30	0	USD	273

Change in accounts receivable

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

Period	Value	Unit	Days
2023-01-01 to 2023-09-30	-706	USD	273
2022-01-01 to 2022-09-30	1,172	USD	273

Change in inventories

The cash flow adjustment for the change in inventories during the period. A positive value under this concept means inventory grew and reduced operating cash flow.

Period	Value	Unit	Days
2023-01-01 to 2023-09-30	-12,919	USD	273
2022-01-01 to 2022-09-30	15,717	USD	273

Inspect the source

Entity: Black Bird Biotech, Inc. / CIK 0001409999
Captured: 2026-09-22 19:47 UTC
SEC response SHA-256: df936db10ff162447a769152b36bd1ddff9f21ac96d53dd4e87253b660581055

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001409999.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))